Sweden - Sweden - Läkemedelsverket (Medical Products Agency)

baxter holding b.v. - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - bortezomib 3,5 mg aktiv substans; mannitol hjälpämne

Sweden - Sweden - Läkemedelsverket (Medical Products Agency)

ever valinject gmbh - bortezomib - injektionsvätska, lösning - 2,5 mg/ml - bortezomib 2,5 mg aktiv substans; mannitol hjälpämne

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Sweden - Sweden - Läkemedelsverket (Medical Products Agency)

reddy holding gmbh - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - mannitol hjälpämne; bortezomib 3,5 mg aktiv substans

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

pfizer europe ma eeig  - rimegepant - migrän störningar - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiska medel - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Sweden - Sweden - Läkemedelsverket (Medical Products Agency)

2care4 aps - ebastin - filmdragerad tablett - 20 mg - ebastin 20 mg aktiv substans

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Kesatuan Eropah - Sweden - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv-infektioner - antivirala medel för systemisk användning - ageneras, i kombination med andra antiretrovirala medel, är indicerat för behandling av proteasinhibitor (pi) erfarna hiv-1-infekterade vuxna och barn över 4 år. ageneraskapslar ska normalt ges med lågdos ritonavir som en farmakokinetisk förstärkare av amprenavir (se avsnitt 4. 2 och 4. valet av amprenavir bör baseras på individuell testning av virusresistens och behandlingshistorik hos patienter (se avsnitt 5. förmån av agenerase förstärkt med ritonavir har inte visats i pi långhuset patienter (se avsnitt 5.